Small molecule activators of the p53 response

Marcus J. G. W. Ladds¹,²,* and Sonia Lain¹,²,*

¹ Department of Microbiology, Tumor and Cell Biology, Biomedicum, Solnavägen 9, Karolinska Institutet, 17165, Stockholm, Sweden
² SciLifeLab, Tomtebodavägen 23A, 171 65, Solna, Stockholm, Sweden
* Correspondence to: Marcus J.G.W. Ladds, E-mail: marcus.ladds@ki.se; Sonia Lain, E-mail: sonia.lain@ki.se

Drugging the p53 pathway has been a goal for both academics and pharmaceutical companies since the designation of p53 as the ‘guardian of the genome’. Through growing understanding of p53 biology, we can see multiple routes for activation of both wild-type p53 function and restoration of mutant p53. In this review, we focus on small molecules that activate wild-type p53 and that do so in a non-genotoxic manner. In particular, we will describe potential approaches to targeting proteins that alter p53 stability and function through posttranslational modification, affect p53’s subcellular localization, or target RNA synthesis or the synthesis of ribonucleotides. The plethora of pathways for exploitation of p53, as well as the wide-ranging response to p53 activation, makes it an attractive target for anti-cancer therapy.

Keywords: cancer, p53, small molecule, cell biology, cancer therapy

Introduction

The tumour suppressor p53 in its role as the ‘guardian of the genome’ exerts a multitude of effects on cells in response to cellular stress (Lane, 1992). As a key transcription factor, it regulates a number of genes involved in cell cycle arrest, apoptosis, senescence, DNA repair, metabolism, autophagy, and ferroptosis (Wynford-Thomas, 1996; Gao et al., 2000; Ryan, 2011; Wang et al., 2016). As it plays such a central role in response to cellular stresses, the pathway is often dysregulated in cancer through either deletion or mutation of p53 itself, upregulation of its negative regulators, or dysfunction of its downstream effectors.

More than one half of solid tumours occurring in adults carry deletions or mutations in TP53, making it one of the most consistently and frequently mutated genes in cancer (Hollstein et al., 1991; Levine et al., 1991; Greenblatt et al., 1994). Whilst this is a significant number, it means that around 50% of solid tumours in adults carry wild type TP53. In addition, many haematological malignancies, tumours associated with viral infection, as well as childhood cancers, seldom carry TP53 mutations. Wild type p53 status is very clearly associated with a positive clinical outcome and to susceptibility to chemoimmunotherapy in patients with chronic lymphocytic leukaemia (Malickova et al., 2018) but this positive association is less clear in other cancer types. Tumours may possess wild type p53, but it may not be fully active and its response to stress may be dampened by alterations in other factors such as amplification of the p53 ubiquitin E3 ligase HDM2, loss of p14ARF tumour suppressor or the expression of oncoviral proteins that inhibit p53 and target it for degradation (Kensuke and Vassilev, 2015). Therefore, promoting p53 expression and function in these tumours could have a beneficial effect for patients.

One salient point to consider is that classic chemotherapeutics and radiation therapy activate p53 by promoting its phosphorylation, which prevents p53 degradation, as well as, perhaps, also promoting p53 synthesis (Takagi et al., 2005; Chen and Kastan, 2010). In this review, we focus on the efforts made to achieve p53 activation in cancers using molecules that, in principle, do not cause damage to the genome, and are therefore less likely to cause irreversible side effects and treatment-related tumours. These strategies include molecules that activate p53 by modulating its posttranslational modifications, localization, synthesis and its degradation.

Targeting posttranslational modifications of p53

Finding small molecules that enhance or prevent modifications of p53 has long been considered a prospective strategy to treat tumours that retain wild type p53. Each of these strategies is summarized in Figure 1.

Received September 11, 2018. Revised December 21, 2018. Accepted January 18, 2019.
© The Author(s) (2019). Published by Oxford University Press on behalf of Journal of Molecular Cell Biology, IBCB, SIBS, CAS. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
Targeting HDM2/HDMX

The p53 protein itself is tightly controlled and maintained at low levels under normal cellular conditions by its primary negative regulator HDM2 (the human homologue of MDM2). HDM2 acts as an E3 ubiquitin ligase, which binds to p53 and subsequently causes its ubiquitination and nuclear export, targeting p53 for proteasomal degradation (Hock and Vousden, 2010). Interestingly, HDM2 participates in a negative feedback loop for p53 as it is also a target gene of p53. The induction of the tumour suppressor p14ARF by oncogenes, and other stress signals, suppresses HDM2 through direct p14ARF binding, providing a positive pressure during cellular stress for p53 activation (Sherr and Weber, 2000; Sherr, 2012). The HDM2 binder, HD MX/HDM4 — itself a structural homologue of HDM2, does not have any E3 ubiquitin ligase activity of its own. However, it does participate in the regulation of p53 through binding to its N-terminus as well as aiding HDM2 to increase ubiquitination of p53 by forming a heterodimer with HDM2 (Huang et al., 2011; Graves et al., 2012).

One of the first reagents published that targeted HDM2 was a 12 amino acid mini-protein derived from the HDM2 binding domain of p53 cloned into the active-site loop of Escherichia coli thioredoxin (Bottger et al., 1997). This protein insert was known as a thioredoxin insert protein (TIP), and the best of these, with an IC_{50} of 300 nM against HDM2, was named superTIP (Bottger et al., 1997). The development of superTIP paved the way for further development of peptide-based therapies including the use of stapled peptides. These peptides utilized a hydrocarbon bridge across the helical binding domain to stabilize its secondary structure, theoretically overcoming the limitation of the superTIP peptide sequence, which does not form a stable secondary structure (Bernal et al., 2007). The stapling of the α-helical portion of the p53 transactivation domain responsible for binding to the hydrophobic cleft of HDM2, stabilized the secondary structure and increased the potency of some peptides to yield a K_{d} as low as 6.76 nM (Brown et al., 2013). Stapled peptides are now reaching clinical trials, with one of the most advanced agents being ALRN-6924, an inhibitor of HDM2 and HD MX interaction with p53, having undergone phase I clinical trial (Meric-Bernstam et al., 2017). ALRN-6924 is currently at the time of writing undergoing further investigation for new phase I clinical trials either as a monotherapy or in combination with current therapeutics.

The first small molecule inhibitor identified as capable of disrupting the p53–HDM2 interaction was 4,5-dihydroimidazoline (nutlin) (Vassilev et al., 2004). The more potent compound, nutlin-3, possessed a chiral centre and demonstrated stereoselective inhibition of HDM2 with nutlin-3a being the active enantiomer. The nutlins spearheaded the development of more potent inhibitors including the chromenotriazolpyrimidine molecules, the terphenyls, the chalcones, and the benzodiazepinedione families (Orner et al., 2001; Go et al., 2005; Grasberger et al., 2005; Allen et al., 2009). Currently, nutlin-like molecules AMG232 (Sun et al., 2014) and idasanutlin (Ding et al., 2013) are both undergoing clinical trials (Table 1).

Targeting Wip1/PPM1D

p53 not only induces the expression of its E3 ligase HDM2 but also acts as a transcription factor for the expression of Wip1/PPM1D (p53: 15) (HDM2: 395). HDM2 acts as an E3 ubiquitin ligase, which binds to p53 and subsequently causes its ubiquitination and nuclear export, targeting p53 for proteasomal degradation (Hock and Vousden, 2010). Interestingly, HDM2 participates in a negative feedback loop for p53 as it is also a target gene of p53. The induction of the tumour suppressor p14ARF by oncogenes, and other stress signals, suppresses HDM2 through direct p14ARF binding, providing a positive pressure during cellular stress for p53 activation (Sherr and Weber, 2000; Sherr, 2012). The HDM2 binder, HD MX/HDM4 — itself a structural homologue of HDM2, does not have any E3 ubiquitin ligase activity of its own. However, it does participate in the regulation of p53 through binding to its N-terminus as well as aiding HDM2 to increase ubiquitination of p53 by forming a heterodimer with HDM2 (Huang et al., 2011; Graves et al., 2012).

One of the first reagents published that targeted HDM2 was a 12 amino acid mini-protein derived from the HDM2 binding domain of p53 cloned into the active-site loop of Escherichia coli thioredoxin (Bottger et al., 1997). This protein insert was known as a thioredoxin insert protein (TIP), and the best of these, with an IC_{50} of 300 nM against HDM2, was named superTIP (Bottger et al., 1997). The development of superTIP paved the way for further development of peptide-based therapies including the use of stapled peptides. These peptides utilized a hydrocarbon bridge across the helical binding domain to stabilize its secondary structure, theoretically overcoming the limitation of the superTIP peptide sequence, which does not form a stable secondary structure (Bernal et al., 2007). The stapling of the α-helical portion of the p53 transactivation domain responsible for binding to the hydrophobic cleft of HDM2, stabilized the secondary structure and increased the potency of some peptides to yield a K_{d} as low as 6.76 nM (Brown et al., 2013). Stapled peptides are now reaching clinical trials, with one of the most advanced agents being ALRN-6924, an inhibitor of HDM2 and HD MX interaction with p53, having undergone phase I clinical trial (Meric-Bernstam et al., 2017). ALRN-6924 is currently at the time of writing undergoing further investigation for new phase I clinical trials either as a monotherapy or in combination with current therapeutics.

The first small molecule inhibitor identified as capable of disrupting the p53–HDM2 interaction was 4,5-dihydroimidazoline (nutlin) (Vassilev et al., 2004). The more potent compound, nutlin-3, possessed a chiral centre and demonstrated stereoselective inhibition of HDM2 with nutlin-3a being the active enantiomer. The nutlins spearheaded the development of more potent inhibitors including the chromenotriazolpyrimidine molecules, the terphenyls, the chalcones, and the benzodiazepinedione families (Orner et al., 2001; Go et al., 2005; Grasberger et al., 2005; Allen et al., 2009). Currently, nutlin-like molecules AMG232 (Sun et al., 2014) and idasanutlin (Ding et al., 2013) are both undergoing clinical trials (Table 1).
PPM1D, another of its negative regulators. This p53 inducible phosphatase 1 not only destabilizes p53 by dephosphorylating serine 15 in p53 (Lu et al., 2005) but also dephosphorylates residue 395 in HDM2, which results in the stabilization of HDM2 (Lu et al., 2007). Furthermore, WIP1/PPM1D is either overexpressed, or mutated leading to increased activity in a variety of cancers expressing wild type p53 (Kleiblova et al., 2013). Thus, inhibitors of this enzyme have been considered as potential anticancer agents for wild-type p53 tumours. However, identifying small molecule inhibitors that have specificity for a particular phosphatase is challenging, and it was not until 2014 that a compound capable of specifically and potently inhibiting WIP1/PPM1D was identified (Gilmartin et al., 2014). This WIP1/PPM1D inhibitor, GSK2830371, can hinder tumour growth in a p53 dependent manner in lymphoma and a neuroblastoma model (Gilmartin et al., 2014; Chen et al., 2016). Although GSK2830371 is a weak inhibitor of proliferation on different cancer cell lines, it dramatically potentiates the effect of MDM2 inhibitors, especially in cells where there is a WIP1/PPM1D overexpression or hyperactivation (Esfandiari et al., 2016).

**Table 1** Ongoing clinical trials of HDM2 inhibitors in combination with standard chemotherapeutics or radiation.

| Compound       | Drug combination | Tumour                                                                 | Trial phase | Status          | Trial identifier |
|----------------|------------------|------------------------------------------------------------------------|-------------|-----------------|-----------------|
| Idasanutlin    | Cytarabine       | Acute myeloid leukaemia                                                | III         | Recruiting      | NCT02545283     |
| None           |                  | Polycythemia vera                                                      | II          | Recruiting      | NCT03287245     |
| None           |                  | Solid tumours                                                         | I           | Active not recruiting | NCT03362723   |
| Ixazomib citrate and dexamethasone | Pegasys | Multiple myeloma                                                     | I and II     | Recruiting      | NCT02633059     |
| Venetoclax and cobimetinib |                  | Acute myeloid leukaemia                                                | I and II     | Recruiting      | NCT02670044     |
| Obinutuzumab and rituximab |                  | Follicular lymphoma                                                   | I and II     | Active not recruiting | NCT02624986   |
| Atezolizumab and cobimetinib |                  | ER” Her2” breast cancer                                               | I and II     | Recruiting      | NCT03566485     |
| Rituximab, obinutuzumab, and venetoclax |                  | Diffuse large B-cell lymphoma                                          | I and II     | Recruiting      | NCT03135262     |
| Atezolizumab and cobimetinib |                  | ER” breast cancer                                                     | I and II     | Recruiting      | NCT03566485     |
| Radiation, alectinib, atezolizumab, vismodegib, temsirolimus, and palbociclib |                  | Glioblastoma                                                          | I and II     | Recruiting      | NCT03158389     |
| AMG232         |                  | Solid tumours or multiple myeloma                                      | I            | Completed       | NCT01723020     |
| Radiation      |                  | Glioblastoma or gliosarcoma                                            | I            | Suspended       | NCT030107780    |
| Decitabine     |                  | Metastatic melanoma                                                   | lb/la        | Active not recruiting | NCT02110355   |
| Trametinib and dabrafenib |                  | Acute myeloid leukaemia                                               | I            | Recruiting      | NCT03041688     |
| Trametinib     |                  | Acute myeloid leukaemia                                               | Ib           | Completed       | NCT02016729     |
| Radiation      |                  | Soft tissue sarcoma                                                   | I            | Recruiting      | NCT03217266     |
| DS-3032b       | Cytarabine       | Acute myeloid leukaemia                                               | I and II     | Not yet recruiting | NCT03634228   |
| None           |                  | Solid tumours and lymphomas                                           | I            | Recruiting      | NCT01877382     |
| None           |                  | Acute myeloid leukaemia                                               | I            | Recruiting      | NCT03671564     |
| None           |                  | Multiple myeloma                                                      | I            | Recruiting      | NCT02579824     |
| None           |                  | FLT3-ITD mutant acute myeloid leukaemia                               | I            | Recruiting      | NCT03552029     |
| None           |                  | Acute myeloid leukaemia, myelodysplastic syndrome                     | I            | Recruiting      | NCT02419369     |
| HDM201         | Trametinib       | Colorectal cancer                                                     | I            | Not yet recruiting | NCT03714958     |
| Ancillary treatment |                  | Advanced solid and haematological TP53 wt tumours                     | I            | Active not recruiting | NCT02143635   |
| LCL161, everolimus, panobinostat, and QBM076 |                  | Colorectal cancer, non-small cell lung carcinoma, triple negative breast cancer, renal cell carcinoma | I            | Recruiting      | NCT02890069     |
| Cytarabine and anthracycline |                  | Leukaemia (both myeloid and acute)                                    | I and II     | Not Yet Recruiting | NCT03736044   |
| Ceritinib and/or trametinib |                  | Neuroblastoma                                                         | I            | Recruiting      | NCT02780128     |
| LX5196         |                  | Uveal melanoma                                                        | I            | Recruiting      | NCT02601378     |
| Ribociclib (LEE011) |                  | Liposarcoma                                                           | I and II     | Active not recruiting | NCT02343172   |
| APG115         | Pembrolizumab    | Metastatic melanoma or advanced solid tumours                         | I and II     | Not Yet Recruiting | NCT03611868   |
| None           |                  | Solid tumours or lymphoma                                             | I            | Recruiting      | NCT02935907     |
| None           |                  | Solid tumours and lymphomas                                           | I            | Recruiting      | NCT03449381     |
| None           |                  | Acute myeloid leukaemia, myelodysplastic syndrome                     | I and II     | Recruiting      | NCT02264613     |
| None           |                  | Pediatric cancer                                                      | I            | Recruiting      | NCT03654716     |
| Paclitaxel     |                  | Solid tumours                                                         | I            | Not Yet Recruiting | NCT03725436     |
Modulating p53 acetylation

The deacetylation of p53 at lysine residues has been implicated in enhancing its subsequent ubiquitination by HDM2 (Gu and Roeder, 1997; Tang et al., 2008). The class III histone deacetylase, SirT1, is one of the key players in p53 deacetylation (Luo et al., 2001). It has been shown that the combination of a SirT1 inhibitor, EX527, alongside DNA damage led to an increased acetylation of p53, though no increase in downstream p53 target genes (Solomon et al., 2006). Other SirT1 inhibitors such as the tenovins and inhaizin have been described to increase p53 levels and function (Lain et al., 2008; Zhang et al., 2012). However, at least in the case of the tenovins, the activation of p53 may be due to additional modes of action of these molecules as it has been shown previously that certain tenovins are capable of demonstrating target engagement with SirT1 without cells responding with a rise in levels or activity of p53 (Ladds et al., 2018a).

In 2002, it was reported that HDM2 is able to promote p53 deacetylation by recruiting a complex containing HDAC1, and therefore HDAC1 inhibition could promote p53 stability and function (Ito et al., 2002). Trichostatin A (TSA) is a potent inhibitor of class I and II mammalian histone deacetylases (HDAC), but not the class III HDACs such as the sirtuins. However, TSA on its own does not substantially increase levels of acetylated p53 (Sachweh et al., 2013). These results do not contradict previous studies on the potentiation of p53 acetylation by TSA, as these studies used cells that either overexpressed p300 acetyltransferase, or were irradiated with UV light, or treated with the DNA-damaging agent etoposide, for TSA to cause a detectable change p53 acetylation (Ito et al., 2001; Solomon et al., 2006). Altogether, these results suggest that in order for inhibitors of deacetylases to exert an effect on p53, acetylation of p53 must be induced prior to the addition of the deacetylase inhibitor.

Targeting deubiquitinases

Another mechanism by which ubiquitination of p53 is altered is through the inhibition of the deubiquitinase USP7. This is responsible for the deubiquitination of both p53 and HDM2, though it displays a preferential activity towards HDM2 (Hu et al., 2006). A decrease in HDM2 ubiquitination leads to stabilization of HDM2, and subsequently to an increase in the ubiquitination and degradation of p53. USP7 has also been implicated in the deubiquitination of a number of key proteins involved in tumour suppression, such as PTEN (Song et al., 2008). In spite of the effects of USP7 inhibitors on multiple proteins, inhibitors of USP7 have been shown to be effective at raising p53 levels in cancer cells, and three such inhibitors, HBX 41108 (Colland et al., 2009), P22077 (Altun et al., 2011), and P5091 (Chauhan et al., 2012) led to p53-dependent effects on cell viability. Recently, two more potent inhibitors of USP7 have been identified, and one of them, FT671, has been shown to destabilize HDM2, increase levels of p53 and transcription of p53 target genes, and inhibit tumour growth in mice (Tumbull et al., 2017).

Targeting NEDDylation

NEDDylation is another posttranslational modification that can be modulated with small molecules. In the case of p53, NEDDylation is favoured by HDM2 and leads to inhibition of the transcription factor function of p53 (Xirodimas et al., 2004). FBXO11 is another factor that promotes p53 NEDDylation and inactivation of p53 (Abida et al., 2007). It is, therefore, not a stretch to postulate that inhibition of NEDDylation may, in principle, activate p53. However, it is also possible that by inhibiting NEDDylation, ubiquitination of p53 may be favoured as both types of modification can occur at the same residues (Xirodimas et al., 2004). Indirect evidence suggests that NEDDylation may favour the detection of p53 in the nucleus, whereas ubiquitinated p53 is primarily detected in the cytoplasm (Brooks and Gu, 2006; Carter et al., 2007). Furthermore, NEDDylation occurs in two ribosomal proteins that modulate p53 degradation, RPL11 and RPS14 (Sundqvist et al., 2009; Zhang et al., 2014). In particular, NEDDylation of RPL11, which is promoted by MDM2, contributes to the nucleolar localization of RPL11, which could be associated with a loss in p53 stabilization. HDM2 also favours NEDDylation of RPS14 as well as being required for its nucleolar localization (Zhang et al., 2014).

MLN4924 (Pevonedistat) (Soucy et al., 2009) is thought to act as an AMP mimetic that forms a covalent adduct with NEDD8 in the catalytic pocket of the NEDD8-activating enzyme component UBA3. This compound has been tested in numerous clinical trials and in combination with 5-azacytidine. Additionally, phase III trials for myelodysplastic syndromes, chronic myelomonocytic leukaemia, or low-blast acute myelogenous leukaemia are recruiting at the time of writing. As with many small molecules targeting mechanisms that affect multiple cellular factors, the biological effect of MLN4924 can occur in the absence of p53 (Soucy et al., 2009). Despite this, it is clear that cellular context, including p53 status, can affect the type response to NEDD8 inhibition (Lin et al., 2010; Blank et al., 2013). For example, p53 knockdown can promote the apoptotic response to MLN4924 treatment in a breast cancer cell line (Lin et al., 2010). In a related study, it was shown that cytostatic activation of p53 with a low-dose of actinomycin D can lead to protection of cancer cells from MLN4924 (Malhab et al., 2016).

Targeting the proteasome

Inhibitors of the proteasome, including the clinically approved bortezomib, rapidly increase p53 protein levels (Williams and McConkey, 2003). Not only is the degradation of p53 inhibited, its localization also remains nuclear upon bortezomib treatment (Williams and McConkey, 2003). Combination of bortezomib with the HDM2 antagonist, nutlin-3, led to synergistic cell kill in a number of different tumour types with wild-type p53 (Ooi et al., 2009). It should be noted that in p53 mutant or null cells, bortezomib has recently been found to act to induce apoptosis through the p53 homologue, p73 (Dabiri et al., 2017).

Inhibition of p53 nuclear export

For p53 to exert its transcription factor function, it requires nuclear localization. HDM2-mediated ubiquitination of p53 causes its nuclear export and subsequent proteasomal degradation (Geyer et al., 2000). Therefore, one of the possible
mechanisms to promote p53 transcription factor function and prevent its degradation may be to block its nuclear export. Leptomycin B was found to be a inhibitor of CRM1, a nuclear export protein (Nishi et al., 1994). Leptomycin B covalently inhibits CRM1 through a Michael addition to a cysteine residue on CRM1 (Kudo et al., 1999), a feature that may explain the potency of this natural compound. Accordingly, leptomycin B is capable of increasing p53 levels and its nuclear localization and do so at very low concentrations (Freedman and Levine, 1998; Lain et al., 1999; Smart et al., 1999; Hietanen et al., 2000; Menendez et al., 2003). However, the use of leptomycin B in the clinic was limited due to its toxicity. New inhibitors of nuclear export have been identified that possess the potency of leptomycin B, but apparently lack the same toxicities (Mutka et al., 2009). Selinexor (KPT-330) is another CRM1 inhibitor currently being evaluated following phase II trials as well as further recruitment of participants for phase III clinical trials for the treatment of various cancers. KPT-8602 is yet another CRM1 blocker being evaluated being evaluated as an anti-cancer agent in a phase I clinical trial (NCT02649790) (Etchin et al., 2017).

**Activation of p53 through depletion of ribonucleotides**

Indirect activation of wild-type p53 by depleting cells of ribonucleotides is another possible strategy to activate p53 without causing DNA damage (Linke et al., 1996). In the past couple of years, targeting of dihydroorotate dehydrogenase (DHODH), a key enzyme in the de novo pyrimidine synthesis pathway, has gained increasing attention following a seminal paper by Sykes et al. (2016) demonstrating that acute myeloid leukaemia (AML) cells could undergo differentiation upon DHODH inhibition. A link between DHODH and p53 induction has been suggested since 2010 in HeLa cells, where p53 degradation is mediated by the action of the E6 viral oncoprotein (Khutormenko et al., 2010). However, it is only recently that it was found that DHODH inhibition results in the increase in p53 at early time-points in a cancer cell line where p53 degradation is mediated by MDM2 (Ladds et al., 2018b). At least part of the induction of p53 in these cells is due to an increase in synthesis. p53 mRNA is relatively unchanged by DHODH inhibitors, meaning that the rise in p53 protein is most likely due to an increase in translation of the mRNA already present. The p53 transcribed appears to be functionally active and able to induce the transcription of p53 target mRNAs. In cells with defective cell-cycle checkpoints, like many tumours, DHODH inhibition led to the accumulation of cells in S-phase and this associated with a lowering of levels of cdc6, a key factor involved in licencing of origins of replication (Blow and Hodgson, 2002; Ervin et al., 2009). It was also shown that DHODH inhibitor treated cells proceed into S-phase with a raised level of p53, a situation that may shift cells towards the death pathway. This is in contrast to the response seen by treating the same cells with nutlin-3 as the cells exhibit a classic p53-induced growth arrest in G1 and G2/M. DHODH inhibitors have been previously shown to be highly effective against various cancers (Hail et al., 2010; O’Donnell et al., 2012; Sykes et al., 2016; Ladds et al., 2018b), and one of the most potent inhibitors, brequinar, even made it to clinical trials in the early 1990s for the treatment of a variety of solid tumours, though it was judged to be too toxic to patients in light of its modest clinical outcomes (Dexter et al., 1985; Arteaga et al., 1989; Natale et al., 1992; Urba et al., 1992; Cody et al., 1993; Maroun et al., 1993; Moore et al., 1993).

In the paper by Sykes et al. (2016), this failure in clinical trials was suggested to be due to the inability of DHODH inhibitors to stop the growth of solid tumours in man and that better outcomes could be expected in the treatment of leukaeemias. In this regard, Bayer has commenced a clinical trial (NCT03404726) with a novel and very potent DHODH inhibitor, BAY2402234. One possible way to exploit DHODH inhibition and minimize any on-target toxicities that DHODH inhibition may have in vivo would be to combine with a relevant therapy. Indeed, we have already shown that combination of a DHODH inhibitor, HZ00/HZ05, with an inhibitor of p53 degradation, nutlin-3, led to a synergistic tumour cell kill both in vitro and in vivo in tumour xenograft studies (Ladds et al., 2018b).

It is not only DHODH within the de novo pyrimidine pathway that has been tested in clinical trials, but also the trifunctional multi-domain enzyme CAD, the enzyme responsible for the first three steps of the de novo pathway. The compound, N-(phosphonacetyl)-L-aspartate (PALA) has been noted for its anti-tumour activity for many years having been tested in both in vivo tumour models as well as in patients (Johnson et al., 1976; Linke et al., 1996). It was found to be an inhibitor of CAD, exerting its activity on cells through that pathway (Collins and Stark, 1971). Cells with functional p53 underwent cell cycle arrest, predominantly in G1, whereas p53 deficient cells progressed through to S-phase and accumulated there (Linke et al., 1996). When further testing was conducted, it was found resistance to PALA was associated with the overexpression of CAD (Chen et al., 2001). The amplification of CAD was found to correlate with a reduction or deficiency in MLH1 or MSH6, two key mismatch repair enzymes (Chen et al., 2001). What is highly interesting is that in a recent article highlights the importance of MLH1 as a key contributor of p53-mediated tumour suppression (Janic et al., 2018). The concomitant upregulation of CAD with loss of a key effector of p53-mediated tumour suppression leading to a loss of the efficaciousness of PALA is an interesting avenue to explore for targeting the pyrimidine ribonucleotide synthetic pathway.

**Nucleolar stress**

Most classic cancer therapeutics, through one means or another, are actually indirectly p53 activators (Weinstein et al., 1997). Many of these compounds, as well as other compounds that activate p53 but are not yet used in the clinic, cause disruption of nucleoli (Rubbi and Milner, 2003). In a model proposed by the discoverers of this association (Vlatkovic et al., 2014), the nucleolus would be an important site for p53 polyubiquitination and is, therefore, required for degradation of p53.

An archetypal example of a classic cancer therapeutic that causes nucleolar disruption as well as p53 activation is
actinomycin D, which at low doses does not lead to detectable levels of DNA damage indicators (Choong et al., 2009). In this case, there is evidence suggesting that inhibition of rDNA transcription by actinomycin D can increase the interaction of MDM2 with free ribosomal proteins, and result in the blockage of MDM2-mediated p53 degradation (Golomb et al., 2014). In view of the results using actinomycin D, it is reasonable to expect that impairment of RNA polymerase function would stabilize and activate p53. Indeed, several RNA polymerase I inhibitors, such as CX5461, demonstrate p53 activation and p53 dependency for their effects on cell viability (Bywater et al., 2012). Other agents that disrupt nucleolar structure are the CX-3543, a small molecule capable of disrupting nucleolin/rDNA G-quadruplex complexes in the nucleolus (Drygin et al., 2009) for which two clinical trials have been completed though the results are, as of yet, not reported, and BMH-21, which induces degradation of RNA polymerase I (Peltonen et al., 2014; Wei et al., 2018).

Interestingly, by using a phenotypic screen for p53 transcription factor function, a high number of tubulin poisons were uncovered to be hits in the screen (Staples et al., 2008). How tubulin poisons increase p53 levels and transcription factor activity is not clear. One contributing mechanism could be related to the appearance of multinucleated cells upon disruption of the mitotic spindle. This disruption causes p53 accumulation in some of the nuclei of the same cell, but an absence in others (Staples et al., 2008). Based on the role for nucleolin in p53 degradation, we propose that p53 will only accumulate in the nuclei that do not contain a nucleolus.

Inhibition of cyclin-dependent kinases

Inhibitors of certain cyclin-dependent kinases (CDKs) are also potent activators of the p53 response. For example R-roscovitine (Seliciclib), which targets multiple CDKs in the nanomolar range, induces the expression of functional p53 in cells (MacCallum et al., 2005). According to the current model, roscovitine may activate p53 by inhibiting HDM2 expression (MacCallum et al., 2005), a feature shared with another broad inhibitor of CDKs, flavopiridol. 5,6-dichloro-1-β-D-ribofuranosylbenzimidazole (DRB), another p53-activating compound also leads to a decrease in MDM2 levels. Because DRB is described as an inhibitor of RNA polymerase II (Yankulov et al., 1995), it can be speculated that the effects of roscovitine and flavopiridol on HDM2 may result

Figure 2 Summary of the potential p53 activation routes and the compounds involved.
from inhibition of the activity of CDK7/9 on the carboxy terminal domain of the large subunit of RNA polymerase II. However, the possibility of these compounds exerting effects though other mechanisms cannot be discarded. Strengthening this assertion was the observation that these compounds cause nucleoli disruption. Regardless of the mechanism responsible for the activation of p53, the premise that CDK7/9 inhibition leads to activation of p53 is supported by studies using a new small molecule targeting CKIα as well as CDK7/9, which has recently shown to cure AML in mice through a mechanism that involves p53-activated pαCDK2 (Minzel et al., 2018). It is worth remembering that in a previous study it was shown that CDK7 not only phosphorylates the RNA polymerase II C-terminal domain, but also the C-terminal residues in p53 and potentially improves the binding of p53 to DNA (Lu et al., 1997).

The inhibition of cell cycle progression through inhibition of CDK4 and CDK1 has been associated with the p53/MDM2 axis. CDK4 and MDM2 amplification are frequently linked in liposarcoma and the combination of inhibitors to each of these enzymes slightly improves the *in vivo* antitumor effect (Laroche-Clary et al., 2017). Further observations are required to consider this combination as an effective strategy. With regards to CDK1, it was reported that inhibition of MDM2 with nutlin and blockage of iASPP phosphorylation using a cyclin B1/CDK1 inhibitor activated p53 in melanoma cells (Lu et al., 2013). Furthermore, this reactivation of p53 cooperated with vemurafenib, a BRAFV600E and BRAFV600K inhibitor, to suppress melanoma growth *in vivo*, by inducing p53-dependent apoptosis and growth suppression.

**Conclusions**

The exploitation of the p53 pathway therapeutically has been a formidable challenge, and one that has been under investigation for more than two decades. As summarized in Figure 2, there are a plethora of possible routes to the same end of activating p53. Of the agents described above, the class of compounds that do not exhibit any effects on cell viability in p53 deficient cells are the MDM2 inhibitors. The compounds, however, that target proteins that exert effects on cells beyond the p53 pathway do exhibit an effect on p53 deficient cells although, in many instances, the type of outcome, such as the stage at which cells arrest in the cell cycle or whether induction of cell death occurs, does depend on the p53 status. It is also frequently seen that MDM2 inhibitors only result in arrest in G1 as well as in G2, and this stalling of the cell cycle is reversible upon removal of the compound. One consequence of this reversibility is limited the efficacy of compounds, furthermore, this may also increase the risk for endoreplication and therefore genomic instability (Shen and Maki, 2010). Moreover, MDM2 inhibitors have been shown to exhibit on-target clinical toxicity (Khoo et al., 2014). Perhaps targeting HDMX as well as HDM2, as demonstrated for the stapled peptides, is a way forward (Chee et al., 2017).

### Table 1

| Study | Method | Outcome |
|-------|--------|---------|
| Parker et al., 1998 | | |
| Shen and Maki, 2002 | | |
| Rubbi and Milner, 2007 | | |
| Sirri et al., 2013 | | |
| Brown and Kuhn, 2018 | | |
| Minzel et al., 2018 | | |
| Lu et al., 2017 | | |
| Laroche-Clary et al., 2017 | | |

Multiple clinical trials where HDM2 inhibitors are combined with standard chemotherapeutics or radiation are ongoing (Table 1). Studies on the combination of HDM2 inhibitors with targeted compounds that also activate the p53 pathway through mechanisms other than MDM2 inhibition, may constitute a strategy to achieve more effective cancer treatments, but these are still scarce. With regards to immunotherapy, it has been recently found that HDM2 family gene amplifications correlate with hyperprogression, that is accelerated tumour growth upon administration of immune checkpoint inhibitors (Kato et al., 2017). Therefore, it is tempting to speculate that inhibitors of HDM2 could have beneficial effects on these patients.

Finally, one must bear in mind that HDM2 inhibitors can protect normal cells from S-phase poisons, mitotic poisons, as well as other agents such as DHDH inhibitors. Therefore, the order in which these agents are administered could be postulated to be of great importance to mitigate an undesirable outcome and to be successful as treatments.

### Funding

This work was supported by grants from the Barn cancerfonden (T)–2014-0038, Cancerfonden (150393 CAN 2014/702), and Swedish Research Council (521-2014-3341).

### Conflict of interest

None declared.

### References

Abida, W.M., Nikolaev, A., Zhao, W., et al. (2007). FBXO11 promotes the Neddylation of p53 and inhibits its transcriptional activity. J. Biol. Chem. 282, 1797–1804.

Allen, J.G., Bourbeau, M.P., Wohltieter, G.E., et al. (2009). Discovery and optimization of chromenotiazolopyrimidines as potent inhibitors of the mouse double minute 2-tumor protein 53 protein-protein interaction. J. Med. Chem. 52, 7044–7053.

Altun, M., Kramer, H.B., Willems, L.I., et al. (2011). Activity-based chemical proteomics accelerates inhibitor development for deubiquitylating enzymes. Chem. Biol. 18, 1401–1412.

Arteaga, C.L., Brown, T.D., Kuhn, J.G., et al. (1997). Phase I clinical and pharmacokinetic trial of Brequinar sodium (DuP 785; NSC 768390). Cancer Res. 49, 4648–4653.

Bernal, F., Tyler, A.F., Korsmeyer, S.J., et al. (2007). Reactivation of the p53 tumor suppressor pathway by a stapled p53 peptide. J. Am. Chem. Soc. 129, 2456–2457.

Blank, J.L., Liu, X.J., Cosmopoulos, K., et al. (2013). Novel DNA damage checkpoints mediating cell death induced by the NEDD8-activating enzyme inhibitor MLN4924. Cancer Res. 73, 225–234.

Blow, J.I., and Hodgson, B. (2002). Replication licensing—defining the proliferative state? Trends Cell Biol. 12, 72–78.

Bottger, A., Bottger, V., Sparks, A., et al. (1997). Design of a synthetic Mdm2-binding mini protein that activates the p53 response in vivo. Curr. Biol. 7, 860–869.

Brooks, C.L., and Gu, W. (2006). p53 ubiquitination: Mdm2 and beyond. Mol. Cell 21, 307–315.

Brown, C.J., Quah, S.T., Jong, J., et al. (2013). Stapled peptides with improved potency and specificity that activate p53. ACS Chem. Biol. 8, 506–512.

Bywater, M.J., Poortinga, G., Sanij, E., et al. (2012). Inhibition of RNA polymerase I as a therapeutic strategy to promote cancer-specific activation of p53. Cancer Cell 22, 51–65.

Carter, S., Bischof, O., Dejean, A., et al. (2007). C-terminal modifications regulate MDM2 dissociation and nuclear export of p53. Nat. Cell Biol. 9, 428–435.
Small molecule activators of the p53 response  |  253

Lain, S., Midgley, C., Sparks, A., et al. (1999). An inhibitor of nuclear export activates the p53 response and induces the localization of HDM2 and p53 to 14A-positive nuclear bodies associated with the PODs. Exp. Cell Res. 248, 457–472.

Lane, D.P. (1992). p53, guardian of the genome. Nature 358, 15–16.

Laroche-Clary, A., Chaire, V., Algeo, M.P., et al. (2017). Combined targeting of MDM2 and CDK4 is synergistic in dedifferentiated liposarcomas. J. Hematol. Oncol. 10, 123.

Levine, A.J., Momand, J., and Finlay, C.A. (1991). The p53 tumour suppressor gene. Nature 351, 453–456.

Lin, J.J., Milhollen, M.A., Smith, P.G., et al. (2010). NEDD8-targeting drug MLN4924 elicits DNA rerepair by stabilizing Cdt1 in S phase, triggering checkpoint activation, apoptosis, and senescence in cancer cells. Cancer Res. 70, 10310–10320.

Linke, S.P., Clarkin, K.C., Di Leonardo, A., et al. (1996). A reversible, p53-dependent G0/G1 cell cycle arrest induced by ribonucleotide depletion in the absence of detectable DNA damage. Genes Dev. 10, 934–947.

Lu, M., Breyssens, H., Salter, V., et al. (2016). Negative control of p53 by Sir2α promotes cell survival under stress. Cell 167, 137–148.

MacCallum, D.E., Melville, J., Frame, S., et al. (2007). Seliciclib (CYC202, Roscovitine) induces cell death in multiple myeloma cells by inhibition of RNA polymerase II-dependent transcription and down-regulation of Mcl-1. Cancer Res. 67, 5399–5407.

Lu, X., Nannenga, B., and Donehower, L.A. (2005). PPM1D dephosphorylates Chk1 and p53 and abrogates cell cycle checkpoints. Genes Dev. 19, 1162–1174.

Luo, J., Nikolayev, A.Y., Imai, S., et al. (2001). Negative control of p53 by Sir2α protects from DNA damage. Cell 107, 137–149.

MacCallum, D.E., Melville, J., Frame, S., et al. (2005). Seliciclib (CYC202, Roscovitine) induces cell death in multiple myeloma cells by inhibition of RNA polymerase II-dependent transcription and down-regulation of Mcl-1. Cancer Res. 65, 5399–5407.

Malikova, J., Tausch, E., Rossi, D., et al. (2018). ERIC recommendations for TP53 mutation analysis in chronic lymphocytic leukemia-update on methodological approaches and results interpretation. Leukemia 32, 1070–1080.

Malhab, L.J., Descamps, S., Delaval, B., et al. (2018). The use of the NEDD8 inhibitor MLN4924 (Pevonedistat) in a cyclotherapy approach to protect wild-type p53 cells from MLN4924 induced toxicity. Sci. Rep. 6, 37775.

Maroun, J., Ruckdeschel, J., Natale, R., et al. (1993). Multicenter phase II study of brequinar sodium in patients with advanced lung cancer. Cancer Chemother. Pharmacol. 32, 64–66.

Menendez, S., Higgins, M., Berkson, R.G., et al. (2003). Nuclear export inhibitor leptomycin B induces the appearance of novel forms of human Mdm2 protein. Br. J. Cancer 88, 636–643.

Mistik-Amernam, F., Saleh, M.N., Infante, J.R., et al. (2017). Phase I trial of a novel stapled ALRNN-6924 disrupting MDMX- and MDM2-mediated inhibition of WT p53 in patients with solid tumors and lymphomas. J. Clin. Oncol. 35, 2505.

Minzel, W., Venkatachalam, A., Fink, A., et al. (2018). Small molecules Co-targeting CK1α and the transcriptional kinases CDK7/9 control AML in preclinical models. Cell 175, 171–185.e25.

Moore, M., Maroun, J., Robert, F., et al. (1993). Multicenter phase II study of brequinar sodium in patients with advanced gastrointestinal cancer. Invest. New Drugs 11, 61–65.

Mukai, S.C., Yang, W.Q., Dong, S.D., et al. (2009). Identification of nuclear export inhibitors with potent anticancer activity in vivo. Cancer Res. 69, 510–517.

Natali, R., Wheeler, R., Moore, M., et al. (1992). Multicenter phase II trial of brequinar sodium in patients with advanced melanoma. Ann. Oncol. 3, 659–660.

Nishi, K., Yoshida, M., Fujiwara, D., et al. (1994). Leptomycin B targets a regulatory cascade of c-myc, a fission yeast nuclear protein, involved in control of higher order chromosome structure and gene expression. J. Biol. Chem. 269, 6320–6324.

Ooi, M.G., Hayden, P.J., Kotoula, V., et al. (2009). Interactions of the Hdm2/p53 and proteasome pathways may enhance the antitumor activity of bortezomib. Clin. Cancer Res. 15, 7153–7160.

Ormer, B.P., Ernst, J.T., and Hamilton, A.D. (2001). Toward proteomimetics: terphenyl derivatives as structural and functional mimics of extended regions of an α-helix. J. Am. Chem. Soc. 123, 5382–5383.

O’Donnell, E.F., Koppaparup, P.R., Koch, D.C., et al. (2012). The aryl hydrocarbon receptor mediates leflunomide-induced growth inhibition of melanoma cells. PLoS One 7, e40926.

Parker, B.W., Kaur, G., Nieves-Neira, W., et al. (1998). Early induction of apoptosis in hematopoietic cell lines after exposure to flavopiridol. Blood 91, 458–465.

Peltonen, K., Collis, L., Liu, H., et al. (2014). A targeting modality for destruction of RNA polymerase I that possesses anticancer activity. Cancer Cell 25, 77–90.

Rubbi, C.P., and Milner, J. (2003). Disruption of the nucleolus mediates stabilization of p53 in response to DNA damage and other stresses. EMBO J. 22, 6068–6077.

Ryan, K.M. (2011). p53 and autophagy in cancer: guardian of the genome meets guardian of the proteome. Eur. J. Cancer 47, 44–50.

Sachweh, S.C., Drummond, C.J., Higgins, M., et al. (2013). Incompatible targets of p53 and HDAC inhibition on p21 expression and cell cycle progression. Cell Death Dis. 4, e533.

Shen, H., and Mak, C.G. (2010). Persistent p21 expression after Nutilin-3a removal is associated with senescence-like arrest in 4N cells. J. Biol. Chem. 285, 23105–23114.

Sherr, C.J. (2012). InK4-Arf locus in cancer and aging. Wiley Interdiscip. Rev. Dev. Biol. 1, 731–741.

Sherr, C.J., and Weber, J.D. (2000). The ARF/p53 pathway. Curr. Opin. Genet. Dev. 10, 94–99.

Sirri, V., Hernandez-Verdun, D., and Roussel, P. (2002). Cyclin-dependent kinases govern formation and maintenance of the nucleolus. J. Cell Biol. 156, 969–981.

Smart, P., Lane, E.B., Lane, D.P., et al. (1999). Effects on normal fibroblasts and neuroblastoma cells of the activation of the p53 response by the nuclear export inhibitor leptomycin B. Oncogene 18, 7378–7386.

Solomon, J.M., Pasupuleti, R., Xu, L., et al. (2006). Inhibition of SIRT1 catalytic activity increases p53 acetylation but does not alter cell survival following DNA damage. Mol. Cell. Biol. 26, 28–38.

Song, M.S., Salmena, L., Carracedo, A., et al. (2008). The deubiquitination and localization of PTEN are regulated by a HAUSP-PML network. Nature 455, 813–817.

Soucy, T.A., Smith, P.G., Milhollen, M.A., et al. (2009). An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer. Nature 458, 732–736.

Staples, O.D., Hollick, J.J., Campbell, J., et al. (2008). Characterization, chemical optimization and anti-tumour activity of a tubulin poison identified by a p53-based proteotypic screen. Cell Cycle 7, 3417–3427.

Sun, D., Li, Z., Rew, Y., et al. (2014). Discovery of AMG 232, a potent, selective, and orally bioavailable MDM2-p53 inhibitor in clinical development. J. Med. Chem. 57, 1454–1472.

Sundqvist, A., Liu, G., Mirsalisiotis, A., et al. (2009). Regulation of nucleolar signalling to p53 through NEDDylation of L11. EMBO Rep. 10, 1132–1139.

Sykes, D.B., Kfouri, Y.S., Mercier, F.E., et al. (2016). Inhibition of dihydroorotate dehydrogenase overcomes differentiation blockade in acute myeloid leukemia. Cell 167, 171–186.e15.

Takagi, M., Absdalson, M.J., McClure, K.G., et al. (2005). Regulation of p53 translation and induction after DNA damage by ribosomal protein L26 and nucleolin. Cell 123, 49–63.

 Tang, Y., Zhao, W., Chen, Y., et al. (2008). Acetylation is indispensable for p53 activation. Cell 133, 612–626.

Turnbull, A.P., Ioannidis, S., Krajewski, W.M., et al. (2017). Molecular basis of USP7 inhibition by selective small-molecule inhibitors. Nature 550, 481–486.
Urba, S., Doroshow, J., Cripps, C., et al. (1992). Multicenter phase II trial of brequinar sodium in patients with advanced squamous-cell carcinoma of the head and neck. Cancer Chemother. Pharmacol. 31, 167–169.

Vassilev, L.T., Vu, B.T., Graves, B., et al. (2004). In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 303, 844–848.

Vlatkovic, N., Boyd, M.T., and Rubbi, C.P. (2014). Nucleolar control of p53: a cellular Achilles’ heel and a target for cancer therapy. Cell. Mol. Life Sci. 71, 771–791.

Wang, S.J., Ou, Y., Jiang, L., et al. (2016). Ferroptosis: a missing puzzle piece in the p53 blueprint? Mol. Cell. Oncol. 3, e1046581.

Wei, T., Najmi, S.M., Liu, H., et al. (2018). Small-molecule targeting of RNA polymerase I activates a conserved transcription elongation checkpoint. Cell Rep. 23, 404–414.

Weinstein, J.N., Myers, T.G., O’Connor, P.M., et al. (1997). An information-intensive approach to the molecular pharmacology of cancer. Science 275, 343–349.

Williams, S.A., and McConkey, D.J. (2003). The proteasome inhibitor bortezomib stabilizes a novel active form of p53 in human LNCaP-Pro5 prostate cancer cells. Cancer Res. 63, 7338–7344.

Wynford-Thomas, D. (1996). p53: guardian of cellular senescence. J. Pathol. 180, 118–121.

Xirodimas, D.P., Saville, M.K., Bourdon, J.C., et al. (2004). Mdm2-mediated NEDD8 conjugation of p53 inhibits its transcriptional activity. Cell 118, 83–97.

Yankulov, K., Yamashita, K., Roy, R., et al. (1995). The transcriptional elongation inhibitor 5,6-dichloro-1-β-D-ribofuranosylbenzimidazole inhibits transcription factor IIH-associated protein kinase. J. Biol. Chem. 270, 23922–23925.

Zhang, J., Bai, D., Ma, X., et al. (2014). hCINAP is a novel regulator of ribosomal protein-HDM2-p53 pathway by controlling NEDDylation of ribosomal protein S14. Oncogene 33, 246–254.

Zhang, Q., Zeng, S.X., Zhang, Y., et al. (2012). A small molecule Inauhzin inhibits SIRT1 activity and suppresses tumour growth through activation of p53. EMBO Mol. Med. 4, 298–312.